How did CDTX's revenue and expenses shift in Q4 2024?

Cidara Therapeutics (CDTX) experienced a significant decline in revenue and a substantial increase in expenses in Q4 2024, resulting in a substantial net loss for the period. 1. **Revenue Shift**: - CDTX's revenue for Q4 2024 was $1.28 million. - This represents a decrease from the previous quarter, indicating a decline in the company's sales or revenue generation capacity. 2. **Expense Shift**: - The cost of goods sold (COGS) for CDTX in Q4 2024 is not provided, but the gross margin was 100%, which means that the company did not incur any COGS relative to its revenue. - However, the company reported a net income of -$52.31 million for the quarter, which suggests that the expenses were significantly higher than the revenue. 3. **Net Income Impact**: - The net income of -$52.31 million indicates that CDTX incurred a substantial loss in Q4 2024. - This net loss is a result of the revenue decline and the increase in expenses, which together paint a picture of a challenging financial period for the company. In conclusion, Cidara Therapeutics faced a difficult financial quarter in Q4 2024, characterized by a drop in revenue and a substantial rise in expenses, leading to a substantial net loss. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Collaboration|1275000|186| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Collaboration|1275000|186| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Collaboration|1275000|186| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Product|2826000|186| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Product|2826000|186| |CDTX|CDTX.O|Cidara Therapeutics|20240101-2024|Collaboration|5637000|186| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q1|-442.71490209093923|-1.0326E7|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q2|-569.4729888432178|-9.1209E7|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q3|-75.52432195014823|-1.5985E7|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q4|-1527.9800809212575|-5.2307E7|186| |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q1|-67.58340674914774|8463000|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q2|-94.06679764243616|302000|186| |code|Ticker|Name|Date|Gross Profit Margin|Gross Profit Margin YoY|market_code| |---|---|---|---|---|---|---| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q1|81.5314|-18.468599999999995|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q2|100|0|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q3|100|0.8425394168275906|186| |CDTX|CDTX.O|Cidara Therapeutics|2024 Q4|100|2.4413830406241575|186|